• KOL
    • Erectile Dysfunction
    • Martin M Miner
    • Martin M Miner: Influence Statistics

      Martin M Miner

      Martin M Miner

      Family Medicine and Urology, Warran Alpert Medical School, Brown University, Providence, Rhode Island, USA | Men’s Health Center, Miriam Hospital, Providence, RI 02906, USA;, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Martin M Miner:Expert Impact

      Concepts for whichMartin M Minerhas direct influence:Erectile dysfunction,Cardiovascular disease,Cardiovascular risk,12 months,Cardiometabolic risk,Testosterone replacement therapy,Testim registry,Testosterone deficiency.

      Martin M Miner:KOL impact

      Concepts related to the work of other authors for whichfor which Martin M Miner has influence:Erectile dysfunction,Prostate cancer,Testosterone therapy,Sexual function,Metabolic syndrome,Cardiovascular disease,Benign prostatic hyperplasia.

      KOL Resume for Martin M Miner

      Year
      2022

      Family Medicine and Urology, Warran Alpert Medical School, Brown University, Providence, Rhode Island, USA

      2021

      Men’s Health Center The Miriam Hotel, Providence, RI, USA

      2020

      Men’s Health Center, Miriam Hospital, Providence, RI, United States

      Men's Health Center, Miriam Hospital Providence, 02901, Rhode Island, USA.

      Brown University, Providence, RI.

      2019

      Men's Health Center, Department of Family and Community Medicine, Department of Family Medicine and Urology, Warren Alpert School of Medicine of Brown University, Providence, RI.

      Departments of Family Medicine and Urology, Men’s Health Center, Miriam Hospital, Brown University, Providence, RI, USA

      2018

      American Urological Association Education and Research, Inc., Linthicum, Maryland.

      Department of Family Medicine, Alpert Medical School of Brown University, Providence, RI (M.M.M.).

      Warren Alpert School of Medicine, Brown University, Providence, RI, USA

      2017

      Providence, RI

      2016

      Brown University Providence RI USA

      Men's Health Center, Providence, RI

      2015

      Department of Family Medicine, The Alpert Medical School of Brown University, Providence, Rhode Island, USA

      2014

      Brown University, Providence, Rhode Island, USA.

      Men's Health Center, Chief of Family and Community Medicine, Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA

      2013

      Miriam Hospital Men’s Health Center, Warren Alpert School of Medicine, Brown University Providence,

      214 N. West Ave, 49201, Jackson, Michigan, USA

      2012

      Department of Family Medicine and Department of Urology, Warren Alpert School of Medicine, Brown University, Providence, RI

      Miriam Hospital Men's Health Center, Warren Alpert School of Medicine, Brown University, Providence, Rhode Island, USA

      2011

      Miriam Hospital Men's Health Center, 164 Summit Avenue, Providence, RI 02906, USA

      The International Society on Men’s Health Testosterone Consensus Group, Warren Albert School of Medicine, Brown University, Providence, RI

      2010

      Men's Health Center, the Miriam Hospital, and the Warren Alpert School of Medicine, Brown University, Providence, Rhode Island

      Brown University School of Medicine, Providence, RI, USA;

      Swansea Family Practice Group, Swansea, MA, USA

      2009

      Men's Health Center, The Miriam Hospital Providence, RI

      Department of Family Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA

      Men’s Health Center, Miriam Hospital, Warren Alpert Medical School, Brown University

      2008

      Men's Health Center, The Miriam Hospital, Warren Alpert School of Medicine, Brown University, Swansea, MA, USA;

      Brown University, Department of Family Medicine, Providence,

      2007

      Division of Biology and Medicine, Department of Family Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA

      Brown University School of Medicine, Providence, Rhode Island

      2006

      Department of Family Medicine, Brown Medical School, Providence, RI, USA

      2005

      Brown Medical School, Box G-A, Providence, RI 02912, USA

      2004

      Swansea Health Center, Swansea, MA, USA

      Sample of concepts for which Martin M Miner is among the top experts in the world.
      Concept World rank
      endopat scores #1
      primary emerging paradigm #1
      patient cardiometabolic risk #1
      vardenafil stopwatch #1
      vardenafil statin #1
      trius cohorts #1
      erectile dysfunction assessment #1
      trt population #1
      stratification cvd #1
      dyslipidemia ldlc levels #1
      hypogonadal users #1
      trius prospective #1
      data testim #1
      responses sep3 #1
      step watchful waiting #1
      678 age #1
      postprostatectomy risk #1
      12 months trt #1
      trt trius cohorts #1
      testosterone deficiency subjects #1
      comorbidities testosterone deficiency #1
      urologic condition #1
      bmsfi subgroups #1
      luts enlarged prostate #1
      849 registrants #1
      hypogonadal middle #1
      3 months trt #1
      aoh exogenous #1
      tth aoh #1
      etiology latest guidelines #1
      intraday level variations #1
      life testim registry #1
      distinguish vasculogenic #1
      metabolic investigation etiology #1
      trt 12 #1
      12month observational registry #1
      testim registry #1
      step simplified treatment #1
      states trius #1
      levels exogenous tth #1
      prescribed testim #1

      Prominent publications by Martin M Miner

      KOL-Index: 15437

      PURPOSE: We measured prostate specific antigen after 12 months of testosterone replacement therapy in hypogonadal men.

      MATERIALS AND METHODS: Data were collected from the TRiUS (Testim® Registry in the United States), an observational registry of hypogonadal men on testosterone replacement therapy (849). Participants were Testim naïve, had no prostate cancer and received 5 to 10 gm Testim 1% (testosterone gel) daily.

      RESULTS: A total of 451 patients with prostate specific antigen and ...

      Known for Testosterone Replacement Therapy | Specific Antigen | 12 Months | Prostate Saturation Theory | Testim Registry
      KOL-Index: 13053

      INTRODUCTION: Up to 30% of erectile dysfunction (ED) patients treated with phosphodiesterase type 5 (PDE5) inhibitors do not show improved sexual function, which may be due in part to low serum testosterone. Hypogonadal patients already receiving testosterone replacement therapy (TRT) likewise can still suffer from symptoms of sexual dysfunction. In these patient populations, augmenting with, or switching, TRT treatment may improve sexual function.

      AIM: To determine if 12-month treatment ...

      Known for Sexual Function | United States | Testim Registry | Testosterone Replacement Therapy | 12 Months
      KOL-Index: 12537

      INTRODUCTION: Cligosiban is an orally administered oxytocin receptor antagonist being developed to treat premature ejaculation (PE).

      AIM: To determine the safety and efficacy of cligosiban capsules (dose range 400-800 mg) to improve intravaginal ejaculation latency time (IELT) and patient-reported outcomes in men with severe lifelong PE.

      METHODS: Patients recorded details of at least 4 sexual intercourse events during a 4-week run-in period, after which they underwent baseline ...

      Known for Oxytocin Antagonist | Ielt Cligosiban | Lifelong Premature | Intravaginal Ejaculatory | Patientreported Outcomes
      KOL-Index: 10825

      BACKGROUND: Recent evidence suggests that there may be a bidirectional, physiological link between hypogonadism and metabolic syndrome (MetS), and testosterone replacement therapy (TRT) has been shown to improve some symptoms of MetS in small patient populations. We examined the effect of 12 months of TRT on MetS components in a large cohort of hypogonadal men.

      METHODS: Data were obtained from TRiUS (Testim® Registry in the United States), a 12-month, multicenter, prospective ...

      Known for 12 Months | Testim Registry | Testosterone Replacement Therapy | Metabolic Syndrome | Waist Circumference
      KOL-Index: 10589

      BACKGROUND: COVID-19 lung segmentation using Computed Tomography (CT) scans is important for the diagnosis of lung severity. The process of automated lung segmentation is challenging due to (a) CT radiation dosage and (b) ground-glass opacities caused by COVID-19. The lung segmentation methodologies proposed in 2020 were semi- or automated but not reliable, accurate, and user-friendly. The proposed study presents a COVID Lung Image Analysis System (COVLIAS 1.0, AtheroPoint™, Roseville, ...

      Known for Lung Segmentation | Computed Tomography | Deep Learning | Vgg Segnet | Artificial Intelligence
      KOL-Index: 10475

      INTRODUCTION: Female sexual function is dependent, in part, upon normal endothelial function within the genital arterial (hypogastric-cavernosal) vascular bed. The first two Princeton Consensus Conferences were focused on relationships between male sexual function and cardiovascular health, and development of contemporary clinical guidelines for dysfunction management.

      AIM: The third Princeton Consensus Conference updated recommendations and assessed, for the first time, the association ...

      Known for Sexual Health | Cardiometabolic Risk | Fsd Women | Cardiovascular Disease | Metabolic Syndrome
      KOL-Index: 10410

      OBJECTIVES: The severity of lower urinary tract symptoms (LUTS) has correlated with erectile dysfunction (ED) and ejaculatory dysfunction (EjD) in large-scale epidemiologic studies. ED and EjD are also side effects of some medical therapies for LUTS suggestive of benign prostatic hyperplasia (LUTS/BPH). These relationships were examined in a physician office-based population of men enrolled in the BPH Registry.

      METHODS: Enrolled men with LUTS/BPH who completed the International Prostate ...

      Known for Sexual Dysfunction | Luts Bph | Lower Urinary | Tract Symptoms | Medical Therapies
      KOL-Index: 10096

      BACKGROUND: Benign prostatic hyperplasia (BPH) is a common disorder in older men and may be associated with lower urinary tract symptoms (LUTS) and sexual dysfunction. Men who present with symptomatic BPH and LUTS are at increased risk for sexual dysfunction, including erectile dysfunction (ED) and ejaculatory dysfunction (EjD).

      OBJECTIVE: This review describes treatment options recommended by the 2003 American Urological Association (AUA) guideline panel for the relief of LUTS ...

      Known for Sexual Function | Prostatic Hyperplasia | Luts Bph | Lower Urinary | Tract Symptoms
      KOL-Index: 9464

      OBJECTIVE: Among patients with hypogonadism-associated comorbidities, opioid users have the highest incidence of hypogonadism. Data from the Testim Registry in the United States were analyzed to determine the efficacy of testosterone replacement therapy in opioid users vs nonusers.

      DESIGN: Prospective, 12-month observational cohort registry.

      SUBJECTS: Hypogonadal men (N = 849) prescribed Testim (but not necessarily testosterone replacement) for the first time.

      INTERVENTIONS: Testim 1% ...

      Known for Opioid Users | Testosterone Replacement | United States | Sexual Function | Testim Registry
      KOL-Index: 9235

      INTRODUCTION: Phosphodiesterase type-5 (PDE-5) inhibitors have previously been evaluated for their efficacy and safety in various clinical trials in men with erectile dysfunction (ED) with or without associated comorbidities.

      AIM: This is the first prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a PDE-5 inhibitor (i.e., vardenafil) in an exclusive population of men with ED and dyslipidemia.

      MAIN OUTCOME MEASURES: Three coprimary ...

      Known for Vardenafil Placebo | Efficacy Safety | Sep2 Sep3 | Outcome Measures | Pde5 Inhibitor
      KOL-Index: 8477

      BACKGROUND: Testosterone deficiency (TD) is prevalent among men seeking medical attention and may be associated with other comorbidities.

      OBJECTIVE: The Testim(®) Registry in the United States (TRiUS), a large, multicenter, prospective, 12-month observational cohort registry, was established to quantify symptoms and comorbidities of hypogonadal men in real-world clinical settings and to evaluate the effect of testosterone replacement therapy (TRT).

      METHODS: Eligible TRiUS participants ...

      Known for Trius Registry | Testosterone Deficiency | Baseline Data | Blood Glucose | Sexual Dysfunction
      KOL-Index: 8396

      BACKGROUND AND PURPOSE: Atherosclerotic plaque tissue rupture is one of the leading causes of strokes. Early carotid plaque monitoring can help reduce cardiovascular morbidity and mortality. Manual ultrasound plaque classification and characterization methods are time-consuming and can be imprecise due to significant variations in tissue characteristics. We report a novel artificial intelligence (AI)-based plaque tissue classification and characterization system.

      METHODS: We hypothesize ...

      Known for Artificial Intelligence | Stroke Risk | Symptomatic Plaque | Optimized Classification | Tissue Characterization
      KOL-Index: 8273

      PURPOSE: We examined the evaluation of and management for lower urinary tract symptoms/benign prostatic hyperplasia by physician specialty (urologist vs primary care physician).

      MATERIALS AND METHODS: The BPH Registry and Patient Survey is a longitudinal, observational, disease registry cohort of patients enrolled from January 2004 to February 2005 in the United States. The survey examines patient outcomes and physician practice patterns in the management of lower urinary tract symptoms ...

      Known for Prostatic Hyperplasia | Primary Physicians | United States | Urinary Tract | Medical Therapy
      KOL-Index: 8240

      PURPOSE: Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alternate genetic evaluation models that address the rising demand for genetic services.

      METHODS: A multidisciplinary consensus conference that included experts, stakeholders, and national organization ...

      Known for Germline Testing | Prostate Cancer | Metastatic Pca | Atm Brca2 | Genetic Services
      KOL-Index: 7939

      * A significant proportion of men with erectile dysfunction (ED) exhibit early signs of coronary artery disease (CAD), and this group may develop more severe CAD than men without ED (Level 1, Grade A). * The time interval among the onset of ED symptoms and the occurrence of CAD symptoms and cardiovascular events is estimated at 2-3 years and 3-5 years respectively; this interval allows for risk factor reduction (Level 2, Grade B). * ED is associated with increased all-cause mortality ...

      Known for Coronary Artery | Erectile Dysfunction | Pde5 Inhibitors | Cardiovascular Disease | Therapy Level

      Key People For Erectile Dysfunction

      Top KOLs in the world
      #1
      Raymond C Rosen†
      erectile dysfunction sexual function premature ejaculation
      #2
      Irwin S Goldstein
      erectile dysfunction smooth muscle sexual medicine
      #3
      John B McKinlay
      erectile dysfunction metabolic syndrome boston area community health
      #4
      Tom F Lue
      erectile dysfunction penile erection rat model
      #5
      Dimitrios G Hatzichristou
      erectile dysfunction intracavernous injection 5 inhibitors
      #6
      Robert J Krane
      blood flow smooth muscle chronic ischemia

      Family Medicine and Urology, Warran Alpert Medical School, Brown University, Providence, Rhode Island, USA | Men’s Health Center, Miriam Hospital, Providence, RI 02906, USA;, martin_miner@brown.edu | Men's Health Center, Miriam Hospital Providence, R

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.